Immunogenicity and safety of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta® in healthy subjects: A randomized, double‐blind trial

• Main Authors: Chris Wynne (Author), Christian Schwabe (Author), Emmanuelle Vincent (Author), Armin Schueler (Author), Janka Ryding (Author), Martin Ullmann (Author), Vishal Ghori (Author), Radmila Kanceva (Author), Michael Stahl (Author)
• Format: Book
• Published: Wiley, 2020-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract MSB11455 is a proposed biosimilar to the currently licensed reference pegfilgrastim (Neulasta®). This study was designed primarily to compare the immunogenicity of MSB11455 and Neulasta®. As secondary objectives, the safety and tolerability of MSB11455 and Neulasta® were also compared. Heal...